The Cancer Panel Collection, for use on the MassARRAY® System, has been designed for targeted, highly multiplexed analysis for profiling a variety of suspected cancer-derived samples including formalin-fixed tissue, fine needle aspirates, or plasma.
Ultrasensitive Panels for Liquid Biopsy
UltraSEEK™ Colon Panel
Using as little as 10 ng of input DNA, the UltraSEEK Colon Panel identifies mutations across KRAS, NRAS, EGFR, and PIK3CA genes in liquid biopsy samples, detecting mutations as low as 0.1% allele frequency.
Product Flyer, Mutation List
UltraSEEK Lung Panel
Using as little as 10 ng of input DNA, the UltraSEEK Lung Panel identifies mutations across BRAF, EGFR, ERBB2, KRAS, and PIK3CA genes in liquid biopsy samples, detecting mutations as low as 0.1% allele frequency.
Product Flyer, Mutation List
Highly Sensitive Panels for Solid Tumor
iPLEX® HS Colon Panel
The iPLEX HS Colon Panel identifies mutations across KRAS, NRAS, EGFR, and PIK3CA genes in solid tissue samples, detecting mutations as low as 1% allele frequency.
Product Flyer, Mutation List
iPLEX HS Lung Panel
The iPLEX HS Lung Panel identifies mutations across BRAF, EGFR, ERBB2, KRAS, and PIK3CA genes from poor and degraded samples such as FFPE tissue, FNA, and cytology blocks, detecting mutations as low as 1% allele frequency.
Product Flyer, Mutation List
Additional Cancer Panels
OncoCarta™ Panel
The OncoCarta Panel includes more than 230 somatic mutations across 19 oncogenes and is ideal for orthogonal validation of NGS-based screening or targeted discovery.
Product Flyer
OncoFOCUS™ Panel
The OncoFOCUS Panel covers 300+ somatic mutations in 4 key oncogenes observed in lung, colorectal, and metastatic tumors including EGFR, KRAS, NRAS, and BRAF. While the panel is designed in 12 multiplexed assays, a novel upfront PCR design requires only 20 nanograms of sample.
Product Flyer, Mutation List, Application Note
LungFUSION™ Panel
The LungFUSION Panel offers a rapid screening method for detecting an oncogenic fusion partner in ALK, RET, or ROS1. Fusion partners in these genes have been correlated with targeted therapies for the treatment of NSCLC. The panel is designed in a single multiplexed assay and offers controls to assess RNA quality, endogenous expression of wild-type lung tissue, and DNA contamination.
Product Flyer
LungCarta® Panel
The LungCarta Panel provides a highly sensitive panel for evaluating more than 250 somatic mutations in 26 genes for targeted profiling in non-small cell lung cancer (NSCLC). Subsets of NSCLC can be further defined at the molecular level by recurrent driver mutations that occur in multiple oncogenes including AKT1, ALK, BRAF, EGFR, ERBB2, KRAS, MET, NRAS, and PIK3CA, which are included in the panel.
Product Flyer